Extensive chronic GVHD is associated with donor blood CD34+ cell count after G-CSF mobilization in non-myeloablative allogeneic PBSC transplantation

[1]  S. Heimfeld,et al.  Effect of Peripheral Blood Stem Cell (PBSC) Graft Composition on Graft Versus Host Disease (GVHD) and Mortality After Allogeneic Transplantation , 2010 .

[2]  J. Wagner,et al.  The effect of the composition of unrelated donor bone marrow and peripheral blood progenitor cell grafts on transplantation outcomes. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  J. Klein,et al.  Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. , 2009, Blood.

[4]  R. Fanin,et al.  Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. , 2009, Blood.

[5]  A. Barrett,et al.  Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. , 2008, Blood.

[6]  J. Bourhis,et al.  Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. , 2008, Experimental hematology.

[7]  M. Remberger,et al.  Risk factors for acute graft-versus-host disease grades II–IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors—a single centre study , 2008, Bone Marrow Transplantation.

[8]  S. Saidman,et al.  Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen , 2007, Bone Marrow Transplantation.

[9]  N. Schmitz,et al.  Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. , 2006, Blood.

[10]  S. Mackinnon,et al.  Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony‐stimulating factor (G‐CSF): impact of age, sex, donor weight and type of G‐CSF used , 2006, British journal of haematology.

[11]  Y. Kawano,et al.  Factors associated with granulocyte colony‐stimulating factor‐induced peripheral blood stem cell yield in healthy donors , 2005, Vox sanguinis.

[12]  J. Serody,et al.  Leukocyte migration and graft-versus-host disease. , 2005, Blood.

[13]  S. Heimfeld,et al.  High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation , 2005, Leukemia.

[14]  M. Remberger,et al.  Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. , 2005, Blood.

[15]  M. Harada,et al.  Factors for PBPC collection efficiency and collection predictors. , 2004, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[16]  J. Serody,et al.  Differential Roles for CCR5 Expression on Donor T Cells during Graft-versus-Host Disease Based on Pretransplant Conditioning1 , 2004, The Journal of Immunology.

[17]  J. Miguel,et al.  Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. , 2003, Blood.

[18]  J. Bourhis,et al.  Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation , 2003, Leukemia.

[19]  S. Heimfeld.  Bone marrow transplantation: how important is CD34 cell dose in HLA-identical stem cell transplantation? , 2003, Leukemia.

[20]  J. Bourhis,et al.  Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. , 2002, Blood.

[21]  R. Storb,et al.  Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. , 2002, Blood.

[22]  E. Montserrat,et al.  Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. , 2002, Blood.

[23]  R. Taichman,et al.  G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4 , 2002, Nature Immunology.

[24]  A. Verdeguer,et al.  Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors , 2002, Transfusion.

[25]  S. Heimfeld,et al.  CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. , 2001, Blood.

[26]  K. Cleary,et al.  Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. , 2001, Blood.

[27]  S. Nilsson,et al.  Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. , 2001, Blood.

[28]  J. Radich,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[29]  Bernhard Moser,et al.  Lymphocyte traffic control by chemokines , 2001, Nature Immunology.

[30]  Y. Gazitt,et al.  Plasma Levels of SDF‐1 and Expression of SDF‐1 Receptor on CD34+ Cells in Mobilized Peripheral Blood of Non‐Hodgkin's Lymphoma Patients , 2001, Stem cells.

[31]  S. Heimfeld,et al.  Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. , 2000, Blood.

[32]  N. Ueno,et al.  Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. , 1999, Blood.

[33]  P. Anderlini,et al.  Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience , 1999, Transfusion.

[34]  P. Ljungman,et al.  Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis , 1998, Bone Marrow Transplantation.

[35]  D. Sutherland,et al.  Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering. , 1998, Cytometry.

[36]  D. Sutherland,et al.  The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. , 1996, Journal of hematotherapy.

[37]  J. Ferrara,et al.  Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. , 1995, Blood.

[38]  P. Ljungman,et al.  Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients. , 1995, Bone marrow transplantation.

[39]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[40]  H. Deeg,et al.  Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. , 1992, Blood.

[41]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.

[42]  G. Sauvageau,et al.  Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation. , 2006, Experimental hematology.

[43]  H. Lee,et al.  Allogeneic Peripheral Blood Stem-Cell Compared With Bone Marrow Transplantation in the Management of Hematologic Malignancies: An Individual Patient Data Meta-Analysis of Nine Randomized Trials , 2005 .

[44]  C. Figdor,et al.  The role of metalloproteinases and adhesion molecules in interleukin-8-induced stem-cell mobilization. , 2000, Seminars in hematology.